The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 25, 2025
Filed:
Oct. 04, 2019
Sloan-kettering Institute for Cancer Research, New York, NY (US);
Tri-institutional Therapeutics Discovery Institute, Inc., New York, NY (US);
Makoto Fushimi, Harrison, NY (US);
Maurizio Scaltriti, New York, NY (US);
Daniel Alan Heller, New York, NY (US);
Carles Monterrubio Martinez, Boston, MA (US);
Amaia Arruabarrena Aristorena, New York, NY (US);
Peter T. Meinke, Scotch Plains, NJ (US);
Michael Andrew Foley, New York, NY (US);
Yasutomi Asano, Chigasaki, JP;
Kazuyoshi Aso, Yokohama, JP;
Hiroki Takahagi, Yokohama, JP;
Yosef Shamay, Zichron Yaakov, IL;
Jose Manuel Baselga Torres, New York, NY (US);
Yusuke Sasaki, Yokohamashi, JP;
Mayako Michino, New York, NY (US);
Sloan-Kettering Institute for Cancer Research, New York, NY (US);
Tri-Institutional Therapeutics Discovery Institute, Inc., New York, NY (US);
Abstract
The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3Kα inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3Kα) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.